Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pre-Screening Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Empowering Patients' Lung Cancer Screening Uptake

NCT06000683
View directory record Official record
Conditions
Lung Cancer
Interventions
Patient education, Referral to financial navigation resources, Patient Reminders, Provider Reminers
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
7
States / cities
Costa Mesa, California • Irvine, California • Laguna Hills, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

NCT04552743
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MGTA-145, Plerixafor
Drug
Lead sponsor
Surbhi Sidana, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Drug-drug Interaction Study

NCT01380743
View directory record Official record
Conditions
Pompe Disease
Interventions
duvoglustat, rhGAA
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 29, 2026, 7:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Treatment and Migraine Headaches

NCT04976985
View directory record Official record
Conditions
Chronic Migraine, Migraine Disorders, Headache Disorders, Headache, Migraine
Interventions
Osteopathic Manipulative Therapy (OMT), Standard of care
Procedure · Other
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 29, 2026, 7:56 AM EDT
Not listed No phase listed Observational

Multiple Myeloma (MM) Quality of Life (QOL) Study

NCT04388735
View directory record Official record
Conditions
Multiple Myeloma, Quality of Life, Symptom, Behavioral
Interventions
Questionnaire
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2020 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

NCT02698891
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Paclitaxel, Neulasta
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 29, 2026, 7:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cancer PRevention Through Enhanced EnvironMenT

NCT06864260
View directory record Official record
Conditions
Cancer Risk
Interventions
Built Environment, Social Environment
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study

NCT04846387
View directory record Official record
Conditions
Healthy
Interventions
Magnetic Resonance Imaging (MRI), Post-Void Residual, Uroflowmetry, Questionaire - AUA Symptom Score
Diagnostic Test · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 29, 2026, 7:56 AM EDT
Not listed Not applicable Interventional

CPAP Adherence Pilot Study Among African Americans

NCT05955287
View directory record Official record
Conditions
Sleep Apnea
Interventions
Telemonitoring, Peer Based, CPAP Education, Usual Care
Behavioral
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 29, 2026, 7:56 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT01413087
View directory record Official record
Conditions
Pancreas, Adenocarcinoma
Interventions
Biological/Vaccine: BC-819
Biological
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Mineola, New York • Philadelphia, Pennsylvania • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 29, 2026, 7:56 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933
View directory record Official record
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
Interventions
e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Withdrawn Not applicable Interventional

Technology-Based Distractions for Minor Procedures

NCT06924814
View directory record Official record
Conditions
Anxiety, Procedural Anxiety
Interventions
Standard of Care, Immersive technology
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

HPV Self-Sampling in Somali Women (Isbaar Project)

NCT05453006
View directory record Official record
Conditions
Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
Interventions
COPAN 552c.80 FLOQSwab
Device
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
3,367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Work-related Screen Time in Health Care Workers During Leisure Time

NCT05106647
View directory record Official record
Conditions
Stress, Burnout, Caregiver
Interventions
Reduce screen time
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 7:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and Prednisone

NCT01425099
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Prednisone
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 29, 2026, 7:56 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

NCT00889655
View directory record Official record
Conditions
Colonoscopy
Interventions
Golytely (polyethylene glycol), MiraLax (polyethylene glycol 3350)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 29, 2026, 7:56 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

NCT02778386
View directory record Official record
Conditions
Toxicity
Interventions
N-Methanocarbathymidine, Placebo Capsule
Drug · Other
Lead sponsor
N&N Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Systematic Pediatric Assessment of Rome Criteria (SPARC)

NCT04773158
View directory record Official record
Conditions
Functional Gastrointestinal Disorders
Interventions
Clinical Decision Support
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
1 Day to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 7:56 AM EDT
Recruiting Not applicable Interventional

Effect of Functional Electrical Stimulation (FES) on Handwriting Rehabilitation After Acquired Brain Injury (ABI)

NCT07774715
View directory record Official record
Conditions
Acquired Brain Injury Including Stroke
Interventions
Functional Electrical Stimulation (FES) on Handwriting Rehabilitation
Combination Product
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 7:56 AM EDT
Recruiting Phase 3 Interventional

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

NCT07441681
View directory record Official record
Conditions
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Survey Administration
Procedure · Drug · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
150
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 7:56 AM EDT